跳至主要内容
临床试验/NCT03247699
NCT03247699已完成不适用

Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule

University Hospital, Basel, Switzerland2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2017年6月12日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
Concentration-time profile in plasma

研究概览

简要总结

Healthy Subjects will receive treatment orally with 120-200ml tap water in fasted state.

Treatment in period A is the "Basel phenotyping cocktail" capsule. Treatment in period B consists of simultaneous intake of isolated formulations. In both study arms peripheral venous and capillary blood (DBS) samples will be drawn

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Age 18-50 years old
  • Caucasian male volunteers
  • Body mass index (BMI)18-30kg/m2,weight more than 50kg
  • Full mental and legal capacity
  • Signed informed consent prior to any study related procedure
  • Ability to communicate in German or English, sufficient to comprehend and adhere to study protocol
  • Systolic blood pressure (SBP) 100-145mmHg, diastolic blood pressure (DBP) 50-90mmHg and heart rate (HR) 45-90bpm (inclusive), measured on the leading arm*, after 5min in the supine position at screening Normal physical examination, vital signs, laboratory workup, and electrocardiogram (ECG)
  • Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening
  • No other conditions or circumstances that might interfere with compliance with study protocol

排除标准

  • Known hypersensitivity to any excipients of the drug formulations.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity.
  • History or presence of smoking (within the last 3months prior to screening) or alcohol or drug abuse
  • Intake of prescribed or otc medications, herbal preparations, and / or vitamin/dietary supplements within 2weeks prior to the intended start of study.
  • Excessive caffeine consumption, defined as >800 mg per day at Screening Intake of food products (immediately before or during study) known to be inducers or inhibitors of CYP450

研究组 & 干预措施

"Basel phenotyping cocktail" capsule

Other

干预措施: "Basel phenotyping cocktail" capsule (Other)

"Basel phenotyping cocktail" individual components

Other

干预措施: "Basel phenotyping cocktail" individual components (Other)

结局指标

主要结局

Concentration-time profile in plasma

时间窗: -5 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours

Concentration-time Profiles assessed in Plasma over several time points measuring parent compounds and corresponding metabolites to calculate metabolic ratios

Concentration-time profile in capillary blood

时间窗: -5 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours

Concentration-time Profile assessed in capillary blood over several time points measuring parent compounds and corresponding metabolites to calculate metabolic ratios

次要结局

未报告次要终点

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验